U.S. Markets closed

Orexo AB (publ) (ORX.ST)

Stockholm - Stockholm Real Time Price. Currency in SEK
14.96-0.84 (-5.32%)
At close: 05:29PM CET
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close15.80
Bid15.00 x 0
Ask15.32 x 0
Day's Range14.96 - 16.64
52 Week Range14.76 - 34.30
Avg. Volume28,825
Market Cap513.843M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.45
Earnings DateApr 27, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est38.00
  • PR Newswire

    Orexo postpones publication of the Annual Report

    Orexo AB (publ), (STO:ORX) (OTCQX:ORXOY), has resolved to postpone the publication of the Annual Report for 2022 to March 28, 2023. The previously announced date for publication was March 24, 2023. The change in date is due to prolonged audit of the financial reporting in the European Single Electronic Format, ESEF.

  • PR Newswire

    Notice of Annual General Meeting of Orexo

    The shareholders in Orexo AB (publ), reg. no. 556500-0600, registered office Uppsala, are summoned to the annual general meeting, to be held on Tuesday 18 April 2023, at 16.00 pm in Orexo's facilities at Rapsgatan 7E in Uppsala, Sweden.

  • PR Newswire

    Orexo submits New Drug Application to FDA for OX124, a high-dose rescue medication for opioid overdose

    Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for its lead pharmaceutical pipeline asset, OX124, a nasal rescue medication for opioid overdose. OX124, is based on Orexo´s drug delivery platform amorphOX® and contains a high-dose of naloxone.